Mitchall G. Clark is VP at Atara Biotherapeutics, Inc. (ATRA). They have made 9 open-market trades across 1 company since 2015, most recently 2018-05-18.
CIK 0001612094
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ATRA | 107,972 | $1.0M |
Shares reported on the most recent Form 4, priced at the 2018-05-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATRA | SELL | 2018-05-18 | 2018-05-21 | $50.03 | $2.6M | -2.7% | -8.7% | -29.6% |
| ATRA | SELL | 2018-05-16 | 2018-05-16 | $46.05 | $414K | +3.5% | -4.4% | -18.3% |
| ATRA | SELL | 2018-03-29 | 2018-04-03 | $40.07 | $898K | +13.6% | +12.9% | +7.0% |
| ATRA | SELL | 2018-03-27 | 2018-03-28 | $37.80 | $3.7M | +3.8% | +9.1% | +3.5% |
| ATRA | SELL | 2018-03-27 | 2018-03-28 | $37.87 | $3.8M | +3.8% | +9.1% | +3.5% |
| ATRA | SELL · 10b5-1 | 2017-11-16 | 2017-11-17 | $14.20 | $47K | -1.4% | +0.3% | +221.2% |
| ATRA | SELL · 10b5-1 | 2017-08-16 | 2017-08-17 | $14.33 | $43K | +11.1% | +14.8% | +3.7% |
| ATRA | SELL | 2017-05-16 | 2017-05-17 | $15.25 | $118K | -11.1% | -14.4% | -4.4% |
| ATRA | SELL · 10b5-1 | 2017-02-16 | 2017-02-16 | $15.96 | $49K | +6.5% | +37.1% | -4.5% |
| ATRA | SELL | 2016-11-16 | 2016-11-17 | $19.53 | $117K | +7.9% | -9.5% | -12.5% |
| ATRA | SELL | 2016-05-16 | 2016-05-18 | $15.15 | $126K | +11.2% | +21.9% | +37.3% |
| ATRA | SELL | 2016-02-16 | 2016-02-18 | $15.35 | $127K | +12.0% | +11.6% | +3.8% |
| ATRA | SELL · 10b5-1 | 2015-11-16 | 2015-11-18 | $31.67 | $132K | -24.2% | -6.6% | -39.5% |
| ATRA | SELL · 10b5-1 | 2015-08-17 | 2015-08-19 | $46.19 | $362K | -24.2% | -6.6% | -6.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.